Looking at Dianthus Therapeutics (NASDAQ:DNTH) and Apollomics (NASDAQ:APLM)

Dianthus Therapeutics ( NASDAQ:DNTH – Get Free Report ) and Apollomics ( NASDAQ:APLM – Get Free Report ) are both small-cap medical companies, but which is the superior business? We’ll compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Rating and Earnings

This table compares Dianthus Therapeutics and Apollomics’ revenue, earnings per share (EPS) and valuation.

Dianthus Therapeutics has higher revenue and earnings than Apollomics.

return

This table compares Dianthus Therapeutics and Apollomics’ net margins, return on equity and return on assets.

Analyst recommendations

This is a summary of recent ratings and recommendations for Dianthus Therapeutics and Apollomics, as reported by MarketBeat.

Dianthus Therapeutics currently has a consensus target price of $44.71, indicating a potential upside of 50.15%. Apollomics has a consensus target price of $2.00, indicating a potential upside of 1,308.45%. Given Apollomics’ higher possible upside, analysts plainly believe Apollomics is more favorable than Dianthus Therapeutics.

Insider and institutional ownership

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 16.6% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that big money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and risk

Dianthus Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Apollomics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. more volatile than the S&P 500.

Summary

Dianthus Therapeutics beats Apollomics on 9 of the 12 factors compared between the two stocks.

About Dianthus Therapeutics

(Get a free report)

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complementary therapies for patients with severe autoimmune and inflammatory diseases. DNTH103, a monoclonal antibody, is in development and is in Phase 2 clinical trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

About Apollomics

(Get a free report)

Apollomics, Inc., a clinical-stage biopharmaceutical company, is engaged in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s product portfolio includes Vebreltinib (APL-101), an orally active, highly selective c-Met inhibitor in Phase 2 clinical trials for the treatment of non-small cell lung cancer; APL-102, an orally active small molecule multiple tyrosine kinase inhibitor, which is in a phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate targeting ErbB1/2/4 signaling pathways that is in phase 1 dose-escalation clinical trials to treat brain cancers. Also in development is uproleselan (APL-106), which is in a phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as a phase 2/3 trial of uproleselan for the treatment of older adults. diagnosed with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company’s pipeline consists of preclinical immuno-oncology product candidates such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers and immuno-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was founded in 2015 and is headquartered in Foster City, California.

Get news and reviews for Dianthus Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dianthus Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.